version01
Development of Innovative Technologies for the Treatment of Pulmonary and Heart Failure to Prolong Human's Life
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Статус исследования в реестре не указан — уточняйте в центре.
- Возраст участников: 18–65 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 100 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (12.2023) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 28 · невключение: 16
Критерии включения
- Patients on an extracorporeal life support system with heart failure:
- Implantation of intravenous ECMO
- Hemodynamic support with vasopressors and/or tonics;
- Procalcitonin level ≥ 1 ng/ml;
- Invasive hemodynamic monitoring;
- Written informed consent.
- Patients on an extracorporeal life support system with pulmonary failure:
- IV ECMO implantation
- High levels of venous and arterial CO2 (CO2> 50 mmHg),
- Low paO2, SvO2, SpO2.
- Invasive hemodynamic monitoring;
- Written informed consent.
- -Patients with left ventricular assistive device implantation:
- LVAD implantation
- Biventricular heart failure IV
- INTERMACS I-III
- Hemodynamic support with vasopressors and/or tonics;
- Procalcitonin level ≥ 0.1 ng/ml;
- Invasive hemodynamic monitoring;
- Written informed consent.
- -Patients in operations with prolonged artificial circulation, hypothermia and circulatory arrest:
- Hemodynamic support with vasopressors and/or tonics;
- Bypass duration> 120 minutes
- Hypothermia ≤ 25 0С
- Circulatory arrest
- Procalcitonin level ≥ 1 ng/ml;
- Invasive hemodynamic monitoring;
- Written informed consent.
Критерии невключения
- Patients on an extracorporeal life support system with heart failure:
- Age less than 18 years old
- Terminal hepatic or renal failure just before the procedure
- Patient's written refusal to participate in the study
- Patients on an extracorporeal life support system with pulmonary failure:
- Age less than 18 years old
- Terminal hepatic or renal failure just before the procedure
- Patient's written refusal to participate in the study
- Patients with left ventricular assistive device implantation:
- Age less than 18 years old
- Acute hepatic or renal failure just before the procedure
- Patient's written refusal to participate in the study
- Patients in operations with prolonged artificial circulation, hypothermia and circulatory arrest:
- Age less than 18 years old
- Terminal hepatic or renal failure just before the procedure
- Patient's written refusal to participate in the study
Источник: ClinicalTrials.gov, NCT05090930 · запись обновлена в реестре 25 октября 2021.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 17
- Extracorporeal life support system with pulmonary and / or heart failure: Cytokine response — 24-48 hours
- Extracorporeal life support system with pulmonary and / or heart failure: SOFA-Score — 24, 48, 72 hours
- Extracorporeal life support system with pulmonary and / or heart failure — Time: first 72 hours
- Patients with left ventricular assist device implantation: Difference of Cytokine response — 24-48 hours
- Patients with left ventricular assist device implantation:vasopressors and / or inotropes — first 72 hours
- Patients with left ventricular assist device implantation:Renal function — first 72 hours
- Patients with left ventricular assist device implantation:Lactate level — first 72 hours
- For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of Cytokine response — 24-48 hours
- For operations with prolonged artificial circulation, hypothermia and circulatory arrest: SOFA-Score — 24, 48, 72 hours
- Extracorporeal life support system with pulmonary and / or heart failure:Difference of mean arterial pressure — 24, 48, 72 hours
Цель исследования
The purpose of the program. Formulation of new treatments for heart and pulmonary failure through using organ-replacing technologies.
Formulation of a clinical protocol and implementation of treatment methods into clinical practice heart and pulmonary failure using organ-replacing technologies.
New methods were created for rehabilitating the function of affected organs after implantation of the LVAD, a total artificial heart, an extracorporeal life-sustaining system will be of great importance, both for Kazakhstan and for states with similar problems of donor organ deficiency, will also improve the effectiveness of surgical treatment and reduce the level of complications and mortality of patients on the extracorporeal life-sustaining system and septic patients.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05090930 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.